Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression 71% Improvement Relative Risk Mortality 91% unadjusted ICU admission 82% unadjusted c19early.org/d Tan et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 72 patients in Philippines Lower progression (p=0.043) and mortality (p=0.0021) Tan et al., J. the ASEAN Federation of Endocrine.., doi:10.15605/jafes.038.01.07 Favors vitamin D Favors control
Association of Vitamin D levels on the Clinical Outcomes of Patients Hospitalized for COVID-19 in a Tertiary Hospital
Tan et al., Journal of the ASEAN Federation of Endocrine Societies, doi:10.15605/jafes.038.01.07
Tan et al., Association of Vitamin D levels on the Clinical Outcomes of Patients Hospitalized for COVID-19 in a Tertiary.., Journal of the ASEAN Federation of Endocrine Societies, doi:10.15605/jafes.038.01.07
Feb 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 135 hospitalized COVID-19 patients in the Philippines, showing higher risk of a poor outcome with vitamin D deficiency.
risk of progression, 71.5% lower, RR 0.29, p = 0.04, high D levels (≥30ng/mL) 7 of 38 (18.4%), low D levels (<20ng/mL) 18 of 34 (52.9%), NNT 2.9, adjusted per study, inverted to make RR<1 favor high D levels (≥30ng/mL), odds ratio converted to relative risk, combined mortality and morbidity, multivariable.
risk of death, 91.1% lower, RR 0.09, p = 0.002, high D levels (≥30ng/mL) 1 of 38 (2.6%), low D levels (<20ng/mL) 10 of 34 (29.4%), NNT 3.7, unadjusted.
risk of ICU admission, 82.1% lower, RR 0.18, p = 0.010, high D levels (≥30ng/mL) 2 of 38 (5.3%), low D levels (<20ng/mL) 10 of 34 (29.4%), NNT 4.1, unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tan et al., 27 Feb 2023, retrospective, Philippines, peer-reviewed, 3 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit